However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Bill Stone, Glenview Trust Company chief investment officer, mentioned his bullish take on Merck (NYSE:MRK) during a recent ...

Merck is attracting bullish attention due to its low valuation and strong dividend, but dark clouds hover over its future.

The prestigious 2025 Prix Galien UK Lifetime Achievement Award was bestowed upon Dame June Raine, Former Chief Executive ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to ...

As Merck moves forward with plans to close their Riverside facility, the company remains committed to its West Point location ...

The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Unlike other recent deals however the ...